Aricept Tablet, Film Coated
NDC Package 62856-246-41
Package Information
Aricept (donepezil hydrochloride) tablets is donepezil is used to treat confusion (dementia) related to Alzheimer's disease. This formulation utilizes a tablet, film coated delivery system. Marketed by Eisai Inc., this product is identified by NDC 62856-246 and is authorized under FDA application NDA020690.
Identification & Billing
- RxCUI: 1100184 - donepezil HCl 23 MG Oral Tablet
- RxCUI: 1100184 - donepezil hydrochloride 23 MG Oral Tablet
- RxCUI: 1100187 - Aricept 23 MG Oral Tablet
- RxCUI: 1100187 - donepezil hydrochloride 23 MG Oral Tablet [Aricept]
- RxCUI: 997220 - donepezil HCl 10 MG Disintegrating Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62856 - Eisai Inc.
- 62856-246 - Aricept
- 62856-246-41 - 10 BLISTER PACK in 1 CARTON / 10 TABLET, FILM COATED in 1 BLISTER PACK
- 62856-246 - Aricept
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (62856-246). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62856-246-41 identifies a specific commercial package of 10 blister pack in 1 carton / 10 tablet, film coated in 1 blister pack of Aricept, a human prescription drug labeled by Eisai Inc.. This tablet, film coated is formulated for oral use and contains donepezil hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eisai Inc. on November 25, 1996. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Donepezil is used to treat confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to function. This medication is an enzyme blocker that works by restoring the balance of natural substances (neurotransmitters) in the brain.
How is this Eisai Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62856024641. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.